Fuccio Lorenzo, Hassan Cesare, Frazzoni Leonardo, Miglio Rossella, Repici Alessandro
Department of Medical and Surgical Sciences, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
Gastroenterology Unit, Nuovo Regina Margherita Hospital, Rome, Italy.
Endoscopy. 2016 Feb;48(2):141-8. doi: 10.1055/s-0034-1393331. Epub 2015 Nov 3.
The management of refractory benign esophageal strictures (RBESs) is challenging. Stent placement has been proposed as a possible rescue strategy. We performed a systematic review and meta-analysis to examine the efficacy of this strategy in the long-term resolution of dysphagia.
PubMed, SCOPUS, and Google Scholar were searched (up to January 2015). Studies recruiting adults with RBES treated with stent placement were eligible. The success, adverse event, and migration rates were pooled by means of a random-effect model to obtain odds with a 95 % confidence interval (CI).
Eighteen studies (444 patients) were eligible for inclusion. The pooled clinical success rate was 40.5 % (95 %CI 31.5 % - 49.5 %), yielding odds of 0.68 (95 %CI 0.46 - 0.98) with high heterogeneity (I(2) = 65.0 %). The meta-regression analysis showed stricture etiology as the only influencing factor. Treatment with self-expanding plastic (SEPSs) and metal stents (SEMSs) did not result in significantly higher success rates than treatment with biodegradable stents (BDSs) (46.2 % vs. 40.1 % vs. 32.9 %, respectively). The migration rate was 28.6 % (95 %CI 21.9 % - 37.1 %), yielding odds of 0.40 (95 %CI 0.28 - 0.59), with migration rates for SEPSs and SEMSs reported as being not significantly higher than BDSs (33.3 % vs. 31.5 % vs. 15.3 %, respectively). The adverse event rate was 20.6 % (95 %CI 15.3 % - 28.1 %), yielding odds of 0.26 (95 %CI 0.18 - 0.39) with no significant difference between stent types (19.4 % vs. 21.9 % vs. 21.9 %, respectively).
Stent placement in patients with RBES is effective in about 40 % of cases. Further studies should investigate whether the clinical success rate varies according to the stricture etiology.(PROSPERO registration number: CRD42015019017.).
难治性良性食管狭窄(RBESs)的治疗具有挑战性。支架置入术已被提议作为一种可能的挽救策略。我们进行了一项系统评价和荟萃分析,以检验该策略在长期缓解吞咽困难方面的疗效。
检索了PubMed、SCOPUS和谷歌学术(截至2015年1月)。纳入招募接受支架置入术治疗的RBES成年患者的研究。通过随机效应模型汇总成功率、不良事件率和移位率,以获得95%置信区间(CI)的比值比。
18项研究(444例患者)符合纳入标准。汇总临床成功率为40.5%(95%CI 31.5% - 49.5%),异质性高(I² = 65.0%),比值比为0.68(95%CI 0.46 - 0.98)。荟萃回归分析显示狭窄病因是唯一的影响因素。自膨式塑料支架(SEPSs)和金属支架(SEMSs)治疗的成功率并不显著高于可生物降解支架(BDSs)治疗(分别为46.2%、40.1%和32.9%)。移位率为28.6%(95%CI 21.9% - 37.1%),比值比为0.40(95%CI 0.28 - 0.59),报道的SEPSs和SEMSs移位率并不显著高于BDSs(分别为33.3%、31.5%和15.3%)。不良事件率为20.6%(95%CI 15.3% - 28.1%),比值比为0.26(95%CI 0.18 - 0.39),不同类型支架之间无显著差异(分别为19.4%、21.9%和21.9%)。
RBES患者支架置入术在约40%的病例中有效。进一步研究应调查临床成功率是否因狭窄病因而异。(PROSPERO注册号:CRD42015019017。)